Repare Therapeutics Inc.
NASDAQ:RPTX
1.32 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 51.133 | 131.83 | 7.6 | 0.135 | 0 | 0 | 0 |
| Cost of Revenue
| 131.203 | 4.184 | 3.344 | 1.787 | 0.968 | 0.407 | 0.102 |
| Gross Profit
| -80.07 | 127.646 | 4.256 | -1.652 | -0.968 | -0.407 | -0.102 |
| Gross Profit Ratio
| -1.566 | 0.968 | 0.56 | -12.237 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 133.593 | 119.066 | 90.047 | 40.091 | 20.995 | 9.906 | 4.401 |
| General & Administrative Expenses
| 33.764 | 32.56 | 26.213 | 14.346 | 5.382 | 2.914 | 1.774 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 33.764 | 32.56 | 26.213 | 14.346 | 5.382 | 2.914 | 1.774 |
| Other Expenses
| 0 | -0.043 | -0.041 | -0.016 | -1.356 | -1.136 | -1.474 |
| Operating Expenses
| 167.357 | 151.626 | 116.26 | 54.437 | 26.377 | 12.82 | 6.175 |
| Operating Income
| -116.224 | -19.796 | -108.66 | -54.302 | -26.377 | -12.82 | -6.175 |
| Operating Income Ratio
| -2.273 | -0.15 | -14.297 | -402.237 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 13.045 | 5.896 | 0.074 | -0.44 | -0.644 | -1.428 | -1.621 |
| Income Before Tax
| -103.179 | -13.9 | -108.586 | -54.742 | -27.021 | -14.248 | -7.796 |
| Income Before Tax Ratio
| -2.018 | -0.105 | -14.288 | -405.496 | 0 | 0 | 0 |
| Income Tax Expense
| -9.383 | 15.147 | -1.678 | -1.325 | 0.195 | 0.035 | 0.147 |
| Net Income
| -93.796 | -29.047 | -106.908 | -53.417 | -27.216 | -14.283 | -7.796 |
| Net Income Ratio
| -1.834 | -0.22 | -14.067 | -395.681 | 0 | 0 | 0 |
| EPS
| -2.23 | -0.69 | -2.83 | -1.45 | -0.74 | -0.9 | -0.49 |
| EPS Diluted
| -2.23 | -0.69 | -2.83 | -1.45 | -0.74 | -0.9 | -0.49 |
| EBITDA
| -114.273 | -17.818 | -107.189 | -53.405 | -25.487 | -13.511 | -7.532 |
| EBITDA Ratio
| -2.235 | -0.152 | -14.278 | -397.319 | 0 | 0 | 0 |